Éditoriaux Défense Sécurité Terrorisme Zones de conflits Logistique Livres de référence Liens
Terre Air Mer Gendarmerie Renseignement Infoguerre Cyber Recherche

U.S. Biodefense Research Makes "Tremendous Progress"

U.S. Biodefense Research Makes "Tremendous Progress"

U.S. biomedical researchers are making great strides in an almost two-year-old effort to bolster the nation's defenses against bioterrorism. The National Institute for Allergies and Infectious Diseases (NIAID) released a report September 29 documenting the progress achieved by a collaboration of government, academic and industrial researchers.

The report says that the initiative has resulted in significant steps toward developing vaccines and treatments for likely bioterror agents such as anthrax, smallpox and plague.

"The increased breadth and depth of biodefense research not only is helping us become better prepared to protect citizens against a deliberately introduced pathogen, it also is helping us tackle the continuous tide of naturally occurring emerging infections such as SARS (severe acute respiratory syndrome) and West Nile virus," says NIAID Director Anthony S. Fauci.

NIAID began the effort to heighten the nation's defenses against bioterror in 2002 by convening an expert panel to consider the threats and the possible responses. The move came just months after a series of anthrax-laden letters had been sent to media outlets and political offices in the United States, ultimately killing five people. The perpetrator of that terrorist act has never been apprehended. Source: Washington File (EUR205), U.S. Department of State, Washington D.C. September 30, 2003. Following is the text of the statement.. The report is available on the Internet: Following is the text of the NIAID press release on the report (begin text).

NIAID Reports 'Tremendous Progress' in Biodefense Research

U.S. Department of Health and Human Services, National Institutes of Health, NIH News, National Institute of Allergy and Infectious Diseases (NIAID), September 29, 2003.

Biomedical researchers in government, academia and industry have made tremendous progress working collaboratively towards developing countermeasures for bioterrorism, according to a report issued today on research funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health.

The "NIAID Biodefense Research Agenda for CDC Category A Agents -- Progress Report" (http://www.niaid.nih.gov/biodefense/research/category_A_Pr ogress_Report.pdf) describes myriad steps the Institute has taken since February 2002 to catalyze the development of vaccines, treatments and diagnostics for the most threatening bioterror agents. It was in February 2002 that NIAID convened the first Blue Ribbon Panel on Bioterrorism and its Implications for Biomedical Research, which provided NIAID with objective expertise on the Institute's biodefense future research plans and helped identify the highest priority areas.

"NIAID has greatly expanded its network of industry and academic partners in biodefense, and together they have made tremendous strides in a very short time towards developing countermeasures to protect all Americans from bioterrorism," says Health and Human Services Secretary Tommy G. Thompson.

"The increased breadth and depth of biodefense research not only is helping us become better prepared to protect citizens against a deliberately introduced pathogen, it also is helping us tackle the continuous tide of naturally occurring emerging infections such as SARS and West Nile virus," says NIAID Director Anthony S. Fauci, M.D.

The 37-page report covers progress on meeting the Blue Ribbon Panel's research recommendations and progress in research on so-called Category A pathogens. The Centers for Disease Control and Prevention's Category A agents are those that cause diseases considered to pose the greatest risk to national security: anthrax, smallpox, plague, botulism, tularemia and viral hemorrhagic fevers.

The progress report outlines specific actions NIAID has taken to prepare bioterror countermeasures. For example, the Institute has developed more than 50 initiatives to stimulate biodefense research, three-quarters of which are brand new. Through these initiatives, NIAID has greatly expanded its support of investigators in academia and partnerships with industry. It has also created new biodefense resources, taken advantage of genomic research advances, and furthered understanding of how microbes cause disease and how the immune system responds to infection.

Highlights from the NIAID biodefense progress report include the following:

  • Partnerships in Product Development

In addition to awarding contracts for second-generation smallpox and anthrax vaccines, NIAID has expanded other collaborative opportunities with industry. For example, the NIAID Biodefense Partnerships program is a new mechanism by which the Institute encourages private-sector research and development of countermeasures. Through this program and a similar initiative that includes academia -- Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics and Diagnostics for Biodefense and SARS -- NIAID is funding 31 grants to companies to develop high-priority biodefense products. In addition to attracting more pharmaceutical and biotechnology companies to infectious disease research, these awards will likely shorten the time from preclinical testing to commercialization of products.

  • Basic Research

NIAID recently awarded eight Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research. This nationwide network of multidisciplinary academic centers will conduct wide- ranging research on infectious diseases and the development of diagnostics, therapeutics and vaccines. In addition, through partnerships with other agencies and companies around the world, NIAID has made a significant investment in sequencing pathogen genomes. Researchers have sequenced genomes representative of all bacteria considered bioterror threats, and are sequencing genomes for at least one strain of every potential viral and protozoal bioterror pathogen. Finally, dozens of grants made to individual investigators at academic institutions nationwide are opening new avenues for improving our ability to prevent, diagnose and treat diseases caused by potential agents of terrorism.

  • Biodefense Research Resources and Facilities

NIAID is funding the construction of new biosafety laboratories around the country to address the serious shortage of such facilities to safely conduct research on biodefense and emerging infectious diseases. It also has developed and expanded contracts to screen new drugs; develop new animal models; establish a reagent and specimen repository; and provide researchers with genomic, proteomic and bioinformatic resources.

  • Immunology

NIAID is funding research to better understand the body's own protective mechanisms. In particular, one recent large-scale grant is funding sophisticated studies of the human innate immune system. Another new set of grants has established a network of researchers focused on studies of the human immune system and biodefense.

  • A complete description of NIAID's biodefense research program is available online.

NIAID is a component of the National Institutes of Health, which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

(end text)


Derniers articles

Verdun 2016 : La légende de la « tranchée des baïonnettes »
Eyes in the Dark: Navy Dive Helmet Display Emerges as Game-Changer
OIR Official: Captured Info Describes ISIL Operations in Manbij
Cyber, Space, Middle East Join Nuclear Triad Topics at Deterrence Meeting
Carter Opens Second DoD Innovation Hub in Boston
Triomphe de St-Cyr : le Vietnam sur les rangs
Dwight D. Eisenhower Conducts First OIR Missions from Arabian Gulf
L’amiral Prazuck prend la manœuvre de la Marine
Airmen Practice Rescuing Downed Pilots in Pacific Thunder 16-2
On ne lutte pas contre les moustiques avec une Kalachnikov...
Enemy Mine: Underwater Drones Hunt Buried Targets, Save Lives
Daesh Publications Are Translated Into Eleven Languages
Opération Chammal : 10 000 heures de vol en opération pour les Mirage 2000 basés en Jordanie
Le Drian : Daech : une réponse à plusieurs niveaux
Carter: Defense Ministers Agree on Next Steps in Counter-ISIL Fight
Carter Convenes Counter-ISIL Coalition Meeting at Andrews
Carter Welcomes France’s Increased Counter-ISIL Support
100-Plus Aircraft Fly in for Exercise Red Flag 16-3
Growlers Soar With B-1s Around Ellsworth AFB
A-10s Deploy to Slovakia for Cross-Border Training
We Don’t Fight Against Mosquitoes With a Kalashnikov
Bug-Hunting Computers to Compete in DARPA Cyber Grand Challenge
Chiefs of US and Chinese Navies Agree on Need for Cooperation
DoD Cyber Strategy Defines How Officials Discern Cyber Incidents from Armed Attacks
Vice Adm. Tighe Takes Charge of Information Warfare, Naval Intelligence
Truman Strike Group Completes Eight-Month Deployment
KC-46 Completes Milestone by Refueling Fighter Jet, Cargo Plane
Air Dominance and the Critical Role of Fifth Generation Fighters
Une nation est une âme
The Challenges of Ungoverned Spaces
Carter Salutes Iraqi Forces, Announces 560 U.S. Troops to Deploy to Iraq
Obama: U.S. Commitment to European Security is Unwavering in Pivotal Time for NATO
International Court to Decide Sovereignty Issue in South China Sea
La SPA 75 est centenaire !
U.S. to Deploy THAAD Missile Battery to South Korea
Maintien en condition des matériels : reprendre l’initiative
La veste « léopard », premier uniforme militaire de camouflage
Océan Indien 2016 : Opérations & Coopération
Truman Transits Strait of Gibraltar
Navy Unveils National Museum of the American Sailor
New Navy, Old Tar
Marcel Dassault parrain de la nouvelle promotion d’officiers de l’École de l’Air
RIMPAC 2016 : Ravitaillement à la mer pour le Prairial avant l’arrivée à Hawaii
Bataille de la Somme, l’oubliée
U.S., Iceland Sign Security Cooperation Agreement
Cléopatra : la frégate Jean Bart entre dans l’histoire du BPC Gamal Abdel Nasser
Surveiller l’espace maritime français aussi par satellite
America's Navy-Marine Corps Team Fuse for RIMPAC 2016
Stratégie France : Plaidoyer pour une véritable coopération franco-allemande
La lumière du Droit rayonne au bout du chemin

Directeur de la publication : Joël-François Dumont
Comité de rédaction : Jacques de Lestapis, Hugues Dumont, François de Vries (Bruxelles), Hans-Ulrich Helfer (Suisse), Michael Hellerforth (Allemagne).
Comité militaire : VAE Guy Labouérie (†), GAA François Mermet (2S), CF Patrice Théry (Asie).